GET DAILY SIGNALSErnexa Therapeutics (ERNA) Q3 2026 Earnings: What Investors Should Watch
Key Takeaways
- Ernexa Therapeutics (ERNA) is expected to report third-quarter 2026 results for the period ended September 30, 2026, with an estimated release date around November 6, 2026.
- Wall Street consensus calls for a loss of $3.84 per share, with revenue expected to be $0, reflecting the company's preclinical-stage, non-revenue-generating status.
- In the prior quarter (Q2 2026), the company posted a loss of $3.40 per share, narrowly missing the $3.30 consensus estimate.
- Investors will focus on cash runway, research and development (R&D) spending, and progress toward an Investigational New Drug (IND) application for its lead candidate, ERNA-101.
- The company completed a 1-for-25 reverse stock split in May 2026 as part of efforts to regain compliance with Nasdaq's minimum bid price requirement.
- For more context, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- You can also explore Trending AI Robots for AI-driven trading ideas and market signals.
Why This Earnings Report Matters
Ernexa Therapeutics (ERNA), formerly known as Eterna Therapeutics, is a preclinical-stage biotech developing cell therapies for cancer and autoimmune disease. Its lead candidates are ERNA-101 for ovarian cancer and ERNA-201 for rheumatoid arthritis. Because the company has no approved products, it generates no meaningful revenue, making each quarterly report primarily a window into spending discipline, cash reserves, and clinical advancement. For investors, the Q3 2026 update matters less for top-line growth and more for signals on capital sufficiency and whether the company can reach key regulatory milestones without excessive shareholder dilution. With a thinly traded stock and a sharp decline over the past year, the earnings event carries outsized importance for sentiment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Are Projecting
Analyst consensus for the third quarter of 2026, ending September 30, 2026, projects a net loss of $3.84 per share on revenue of $0. The single-analyst estimate is unchanged over recent months, according to earnings aggregators. This compares with a reported loss of $3.40 per share in Q2 2026, which missed the $3.30 estimate by about 3%, and a loss of $3.75 per share in the year-ago Q3 2025 period.
Given the company's preclinical stage, traditional revenue and earnings metrics offer limited insight. Instead, investors are likely to scrutinize operating expenses, particularly R&D spending tied to ERNA-101's IND-enabling studies, as well as general and administrative costs. In Q1 2026, total operating expenses rose to $5.6 million, up from $2.7 million a year earlier, driven partly by higher study fees and payroll.
Cash is the pivotal metric. The company reported roughly $9.2 million in cash and equivalents as of March 31, 2026, bolstered by a February 2026 public offering that raised approximately $9.5 million in net proceeds. However, management has stated that available cash may be insufficient to fund operations for the next twelve months without additional capital, a point likely to dominate the earnings discussion.
How the Market Is Approaching the Report
Sentiment heading into the Q3 2026 report remains cautious. The stock has declined more than 90% over the past year and trades in the low single digits, with a beta above 2.0 indicating volatility well above the broader market. The company's May 2026 reverse stock split and Nasdaq compliance notices have added to investor unease, while the Q2 2026 earnings miss reinforced concerns about execution and spending.
Key risk factors ahead of the release include potential dilution from additional equity raises, uncertainty around the timing of the IND submission for ERNA-101, and the ongoing going-concern disclosure. Because the stock is thinly traded, earnings-related moves can be magnified. Investors will be watching not only the headline loss per share but also any commentary on the cash position and access to the company's At-the-Market (ATM) equity offering program. From what I see, these factors could influence short-term price action more than the actual loss figure.
Looking Ahead: What to Watch After the Release
Following the Q3 2026 report, the central question for investors will be whether Ernexa Therapeutics can extend its cash runway far enough to reach its next development milestones. Management has guided toward completing IND-enabling studies and submitting an IND application for ERNA-101 in 2026, with a Phase 1 investigator-sponsored clinical trial anticipated in the second half of the year. Any update on this timeline will be closely watched.
Capital structure will remain a defining theme. With cash that management has described as insufficient to fund the next twelve months, further equity issuance is a realistic possibility, and investors should monitor share count and dilution alongside any updates to the ATM program. Continued access to capital markets is essential to the company's survival given its accumulated deficit.
Finally, watch for updates on Nasdaq listing compliance following the May 2026 reverse split, as well as any new data or regulatory feedback on the ERNA-101 and ERNA-201 programs. While the company is early-stage and pre-revenue, progress on these clinical and financial fronts will shape how the market interprets the next several quarters. I’m watching this closely as the timeline for regulatory milestones could shift sentiment quickly.
Using AI Tools in My Research Process
In my own analysis of names like ERNA, I often turn to Tickeron’s AI Screener to quickly filter for comparable biotech stocks based on volatility, cash metrics, and technical patterns. It helps surface ideas that align with the specific factors I’m tracking in an earnings report like this one, saving time while keeping the focus on data-driven comparisons rather than manual reviews.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ERNA in -9.41% downward trend, sliding for three consecutive days on November 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ERNA declined for three days, in 378 of 389 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for ERNA entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ERNA's RSI Indicator exited the oversold zone, 45 of 51 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 64 cases where ERNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for ERNA just turned positive on October 21, 2026. Looking at past instances where ERNA's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Following a +8.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where ERNA advanced for three days, in 153 of 189 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ERNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.704) is normal, around the industry mean (3.482). P/E Ratio (-4.707) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. ERNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biomedical research products in the field of stem cells and regenerative medicine
Industry Biotechnology
Advertisement